Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial

BACKGROUND—: Vorapaxar reduces cardiovascular death, myocardial infarction (MI), or stroke in patients with previous MI while increasing bleeding. Patients with diabetes mellitus (DM) are at high risk of recurrent thrombotic events despite standard therapy and may derive particular benefit from anti...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Circulation
Main Authors: Cavender, Matthew A., Scirica, Benjamin M., Bonaca, Marc P., Angiolillo, Dominick J., Dalby, Anthony J., Dellborg, Mikael, Morais, Joao, Murphy, Sabina A., Ophuis, Ton Oude, Tendera, Michal, Braunwald, Eugene, Morrow, David A.
Format: Artigo
Sprog:Inglês
Udgivet: Lippincott Williams & Wilkins 2015
Fag:
Original Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4365950/
https://ncbi.nlm.nih.gov/pubmed/25681464
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.114.013774
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker